Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after …
A Strezova, J Diez-Domingo… - Open Forum …, 2022 - academic.oup.com
A Strezova, J Diez-Domingo, K Al Shawafi, JC Tinoco, M Shi, P Pirrotta…
Open Forum Infectious Diseases, 2022•academic.oup.comApproximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an
interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy
against herpes zoster remained high. Moreover, the safety profile remained clinically
acceptable, suggesting that the clinical benefit of the RZV in≥ 50-year-olds is sustained up
to 10 years.
interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy
against herpes zoster remained high. Moreover, the safety profile remained clinically
acceptable, suggesting that the clinical benefit of the RZV in≥ 50-year-olds is sustained up
to 10 years.
Abstract
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
Oxford University Press